WO1999044622A1 - Inorganic nitrite and organic acid in combination as topical antiviral composition - Google Patents

Inorganic nitrite and organic acid in combination as topical antiviral composition Download PDF

Info

Publication number
WO1999044622A1
WO1999044622A1 PCT/GB1999/000605 GB9900605W WO9944622A1 WO 1999044622 A1 WO1999044622 A1 WO 1999044622A1 GB 9900605 W GB9900605 W GB 9900605W WO 9944622 A1 WO9944622 A1 WO 9944622A1
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutically acceptable
concentration
acid
use according
weight
Prior art date
Application number
PCT/GB1999/000605
Other languages
English (en)
French (fr)
Inventor
Anthony Ormerod
Nigel Benjamin
Original Assignee
Aberdeen University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to PL99342755A priority Critical patent/PL342755A1/xx
Priority to MXPA00008583A priority patent/MXPA00008583A/es
Priority to EP99937878A priority patent/EP1059928A1/en
Priority to HU0101374A priority patent/HUP0101374A3/hu
Priority to CA002322199A priority patent/CA2322199A1/en
Priority to BR9908617-4A priority patent/BR9908617A/pt
Priority to KR1020007009698A priority patent/KR20010041527A/ko
Priority to JP2000534223A priority patent/JP2002505295A/ja
Application filed by Aberdeen University filed Critical Aberdeen University
Priority to NZ506678A priority patent/NZ506678A/xx
Priority to AU32617/99A priority patent/AU758264B2/en
Priority to US09/330,654 priority patent/US6709681B2/en
Publication of WO1999044622A1 publication Critical patent/WO1999044622A1/en
Priority to NO20004302A priority patent/NO20004302L/no
Priority to US10/701,295 priority patent/US20040105898A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Definitions

  • the present invention relates to a complex of nitrogen oxides, arising from the interaction of nitrite and acid as an 5 antiviral composition for the treatment of viral diseases of the skin by topical application thereto.
  • nitrogen oxide include particular NO which is of the importance particularly if acidified.
  • US-A-5648101 provides a vaso-active composition comprising NO adapted for delivery to a body site inter alia by means of a 5 cream or ointment.
  • the NO is generated from an admixture of ferrous sulphate, an organic acid and an inorganic nitrite and caused to be reactive in the presence of moisture adjacent or at the site. Acidification is not discussed.
  • Another object of the invention is to provide a system for treatment of viral skin diseases which is less susceptible to mutation of viral DNA.
  • the pharmaceutically acceptable acidifying agent or the pharmaceutically acceptable donor of nitrogen oxides or a precursor therefor is disposed in a pharmaceutically acceptable carrier or diluent therefor.
  • the first and second waxy components comprise a paraffin.
  • the acidifying agent is preferably a reducing organic acid or salt such as ascorbic acid or ascorbyl palmitate.
  • the source of nitrogen oxides may be an alkali metal nitrite such as sodium nitrite.
  • a reducing acid or salt thereof results in a product at the environment of use which comprises a major amount of NO which has significant and therapeutic and immunological effects .
  • the antigen processing cells of the skin were seen to lose dendricity and drop from the epidermis so there were significantly fewer in the treated skin. As these cells behave in this way when activated and functioning to process a newly recognized antigen, this would seem to offer further evidence for an immunopotentiating role for the nitrogen oxide complex. Ki-67 staining for dividing cells did not differ in control or active sites. This would suggest that in warts, for example, the action is not one of reducing cell proliferation. - 20 -

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PCT/GB1999/000605 1994-02-21 1999-03-01 Inorganic nitrite and organic acid in combination as topical antiviral composition WO1999044622A1 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
KR1020007009698A KR20010041527A (ko) 1998-03-02 1999-03-01 국소적 항바이러스성 조성물로서 무기 아질산염 및유기산의 조성
EP99937878A EP1059928A1 (en) 1998-03-02 1999-03-01 Inorganic nitrite and organic acid in combination as topical antiviral composition
HU0101374A HUP0101374A3 (en) 1998-03-02 1999-03-01 Inorganic nitrite and organic acid in combination as topical antiviral composition
CA002322199A CA2322199A1 (en) 1998-03-02 1999-03-01 Inorganic nitrite and organic acid in combination as topical antiviral composition
BR9908617-4A BR9908617A (pt) 1998-03-02 1999-03-01 Nitroto inorgânico e ácido orgânico em combinação como uma composição antiviral tópica.
PL99342755A PL342755A1 (en) 1998-03-02 1999-03-01 Inorganic nitrite and organic acid containing compositions as alocally acting antiviral preparations
JP2000534223A JP2002505295A (ja) 1998-03-02 1999-03-01 局所抗ウイルス組成物として組み合わせた無機亜硝酸塩及び有機酸
MXPA00008583A MXPA00008583A (es) 1998-03-02 1999-03-01 Nitrito inorganico y acido organico en combinacion como una composicion antiviral topica.
NZ506678A NZ506678A (en) 1998-03-02 1999-03-01 Inorganic nitrite and organic acid in combination as topical antiviral composition
AU32617/99A AU758264B2 (en) 1998-03-02 1999-03-01 Inorganic nitrite and organic acid in combination as topical antiviral composition
US09/330,654 US6709681B2 (en) 1995-02-17 1999-06-11 Acidified nitrite as an antimicrobial agent
NO20004302A NO20004302L (no) 1998-03-02 2000-08-29 Kombinasjon av uorganisk nitritt og organisk syre som topisk antiviral sammensetning
US10/701,295 US20040105898A1 (en) 1994-02-21 2003-11-03 Acidified nitrite as an antimicrobial agent

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9804469.6 1998-03-02
GBGB9804469.6A GB9804469D0 (en) 1998-03-02 1998-03-02 Antiviral composition

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
PCT/GB1995/000338 Continuation-In-Part WO1995022335A1 (en) 1994-02-21 1995-02-17 Acidified nitrite as an antimicrobial agent
US69693096A Continuation-In-Part 1994-02-21 1996-08-21

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US09/330,654 Continuation-In-Part US6709681B2 (en) 1994-02-21 1999-06-11 Acidified nitrite as an antimicrobial agent
US09/330,654 Continuation US6709681B2 (en) 1994-02-21 1999-06-11 Acidified nitrite as an antimicrobial agent

Publications (1)

Publication Number Publication Date
WO1999044622A1 true WO1999044622A1 (en) 1999-09-10

Family

ID=10827886

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1999/000605 WO1999044622A1 (en) 1994-02-21 1999-03-01 Inorganic nitrite and organic acid in combination as topical antiviral composition

Country Status (14)

Country Link
EP (1) EP1059928A1 (no)
JP (1) JP2002505295A (no)
KR (1) KR20010041527A (no)
CN (1) CN1270725C (no)
AU (1) AU758264B2 (no)
BR (1) BR9908617A (no)
CA (1) CA2322199A1 (no)
GB (1) GB9804469D0 (no)
HU (1) HUP0101374A3 (no)
MX (1) MXPA00008583A (no)
NO (1) NO20004302L (no)
NZ (1) NZ506678A (no)
PL (1) PL342755A1 (no)
WO (1) WO1999044622A1 (no)

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002017881A2 (en) * 2000-08-30 2002-03-07 Queen Mary & Westfield College Transdermal pharmaceutical delivery composition
WO2003013489A1 (en) * 2001-08-03 2003-02-20 Aberdeen University Treatment of nail infections with no
US8557300B2 (en) 2005-05-19 2013-10-15 University Of Cincinnati Methods for treating bacterial respiratory tract infections in an individual using acidified nitrite
WO2014031491A2 (en) * 2012-08-23 2014-02-27 Nioxx Llc Extended production of nitric oxide from microencapsulated chemical reactants
US8795649B2 (en) 2007-02-28 2014-08-05 Invasive Animals Ltd. Nitrite salts as poisons in baits for omnivores
US8927030B2 (en) 2003-07-09 2015-01-06 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of nitrite salts for the treatment of cardiovascular conditions
US8932650B2 (en) * 2011-01-11 2015-01-13 Kantian Skincare LLC Multifunctional topical formulation for the treatment of acne vulgaris and other skin conditions
EP3158990A1 (en) 2015-10-21 2017-04-26 Glano Tech Ltd Formulation for release of nitric oxide
EP3166593A4 (en) * 2014-07-11 2018-02-07 Novan, Inc. Topical antiviral compositions and methods of using the same
US10322082B2 (en) 2014-07-11 2019-06-18 Novan, Inc. Topical antiviral compositions and methods of using the same
US10716805B2 (en) 2018-03-19 2020-07-21 Glanotech Limited Formulation for release of nitric oxide
WO2020245574A1 (en) 2019-06-04 2020-12-10 Thirty Respiratory Limited Methods and compositions for generating nitric oxide and uses thereof to deliver nitric oxide via the respiratory tract
WO2020245573A1 (en) 2019-06-04 2020-12-10 Thirty Holdings Limited Methods and compositions for generating nitric oxide and uses thereof
US11077194B2 (en) 2012-03-14 2021-08-03 Novan, Inc. Nitric oxide releasing pharmaceutical compositions
WO2021214440A1 (en) 2020-04-23 2021-10-28 Thirty Respiratory Limited Nitric oxide or nitric oxide releasing compositions for use in treating sars-cov and sars-cov-2
WO2021214439A1 (en) 2020-04-23 2021-10-28 Thirty Respiratory Limited Methods and compositions for treating and combatting tuberculosis
US11285098B2 (en) 2013-02-28 2022-03-29 Novan, Inc. Topical compositions and methods of using the same
US11285171B2 (en) 2018-03-01 2022-03-29 Novan, Inc. Nitric oxide releasing suppositories and methods of use thereof
US11813284B2 (en) 2013-08-08 2023-11-14 Novan, Inc. Topical compositions and methods of using the same

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130330244A1 (en) * 2011-12-05 2013-12-12 Nioxx Llc Compositions and methods for topical nitric oxide generation
CN109437134A (zh) * 2018-10-26 2019-03-08 中国核电工程有限公司 氮氧化物的制备方法及装置
CN116617254A (zh) * 2022-09-26 2023-08-22 杭州泽德医药科技有限公司 含硼酸、亚硝酸盐的抗病原微生物组合物及应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4923899A (en) * 1987-12-22 1990-05-08 Cetylite Industries, Inc. Sterilant composition
WO1995022335A1 (en) * 1994-02-21 1995-08-24 Aberdeen University Acidified nitrite as an antimicrobial agent
US5573786A (en) * 1993-06-23 1996-11-12 Solco Basel Ag Preparation for skin and mucous membrane

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4923899A (en) * 1987-12-22 1990-05-08 Cetylite Industries, Inc. Sterilant composition
US5573786A (en) * 1993-06-23 1996-11-12 Solco Basel Ag Preparation for skin and mucous membrane
WO1995022335A1 (en) * 1994-02-21 1995-08-24 Aberdeen University Acidified nitrite as an antimicrobial agent

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
"Sodium Nitrite", MATERIAL SAFETY DATA SHEET, 12 August 1996 (1996-08-12), XP002111729, Retrieved from the Internet <URL:www.jtbaker.com/msds/s4466.htm> [retrieved on 19990803] *
HEATON C. L.: "The revival of nitric acid for the treatment of anogenital warts", CLINICAL PHARMACOLOGY &THERAPEUTICS, vol. 54, no. 1, July 1993 (1993-07-01), pages 107 - 111, XP002111731 *
WELLER R. ET AL: "A randomized trial of acidified nitrite cream in the treatment of tinea pedis", JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, vol. 38, no. 4, April 1998 (1998-04-01), pages 559- - 563, XP002111730 *
YOSHIDA Y ET AL: "Induction and promotion of forestomach tumors by sodium nitrite in combination with ascorbic acid or sodium ascorbate in rats with or without N-methyl-N'-nitro-N-nitrosoguanidine pre-treatment.", INTERNATIONAL JOURNAL OF CANCER, (1994 JAN 2) 56 (1) 124-8., XP002111728 *

Cited By (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002017881A2 (en) * 2000-08-30 2002-03-07 Queen Mary & Westfield College Transdermal pharmaceutical delivery composition
US8128964B2 (en) 2000-08-30 2012-03-06 Queen Mary & Westfield College Transdermal pharmaceutical delivery composition
WO2002017881A3 (en) * 2000-08-30 2003-04-17 Queen Mary & Westfield College Transdermal pharmaceutical delivery composition
US8114442B2 (en) 2000-08-30 2012-02-14 Queen Mary & Westfield College Transdermal pharmaceutical delivery compositions
AU2002318001B2 (en) * 2001-08-03 2007-02-15 Aberdeen University Treatment of nail infections with NO
HRP20040059B1 (en) * 2001-08-03 2008-05-31 Aberdeen University Treatment of nail infections with no
WO2003013489A1 (en) * 2001-08-03 2003-02-20 Aberdeen University Treatment of nail infections with no
US9381381B2 (en) 2001-08-03 2016-07-05 Aberdeen University Treatment of nail infections with no
US9700578B2 (en) 2003-07-09 2017-07-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of nitrite salts for the treatment of cardiovascular conditions
US8927030B2 (en) 2003-07-09 2015-01-06 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of nitrite salts for the treatment of cardiovascular conditions
US9675637B2 (en) 2003-07-09 2017-06-13 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of nitrite salts for the treatment of cardiovascular conditions
US9387224B2 (en) 2003-07-09 2016-07-12 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Treatment of specific cardiovascular conditions with nitrite
US8557300B2 (en) 2005-05-19 2013-10-15 University Of Cincinnati Methods for treating bacterial respiratory tract infections in an individual using acidified nitrite
US9750242B2 (en) 2007-02-28 2017-09-05 Invasive Animals Ltd. Nitrite salts as poisons in baits for omnivores
US8795649B2 (en) 2007-02-28 2014-08-05 Invasive Animals Ltd. Nitrite salts as poisons in baits for omnivores
US8932650B2 (en) * 2011-01-11 2015-01-13 Kantian Skincare LLC Multifunctional topical formulation for the treatment of acne vulgaris and other skin conditions
US11077194B2 (en) 2012-03-14 2021-08-03 Novan, Inc. Nitric oxide releasing pharmaceutical compositions
WO2014031491A3 (en) * 2012-08-23 2014-05-30 Nioxx Llc Production of nitric oxide from microencapsulated reactants
US9445996B2 (en) 2012-08-23 2016-09-20 Nioxx Llc Extended production of nitric oxide from a microencapsulated nitrite salt and an aqueous acidified gel
WO2014031491A2 (en) * 2012-08-23 2014-02-27 Nioxx Llc Extended production of nitric oxide from microencapsulated chemical reactants
US11285098B2 (en) 2013-02-28 2022-03-29 Novan, Inc. Topical compositions and methods of using the same
US11813284B2 (en) 2013-08-08 2023-11-14 Novan, Inc. Topical compositions and methods of using the same
US10322081B2 (en) 2014-07-11 2019-06-18 Novan, Inc. Topical antiviral compositions and methods of using the same
US10736839B2 (en) 2014-07-11 2020-08-11 Novan, Inc. Topical antiviral compositions, delivery systems, and methods of using the same
EP3698775A1 (en) * 2014-07-11 2020-08-26 Novan Inc. Topical antiviral compositions and methods of using the same
US10322082B2 (en) 2014-07-11 2019-06-18 Novan, Inc. Topical antiviral compositions and methods of using the same
US11040006B2 (en) 2014-07-11 2021-06-22 Novan, Inc. Topical antiviral compositions, delivery systems, and methods of using the same
EP3166593A4 (en) * 2014-07-11 2018-02-07 Novan, Inc. Topical antiviral compositions and methods of using the same
US11723858B2 (en) 2014-07-11 2023-08-15 Novan, Inc. Topical antiviral compositions, delivery systems, and methods of using the same
EP3158990A1 (en) 2015-10-21 2017-04-26 Glano Tech Ltd Formulation for release of nitric oxide
US11285171B2 (en) 2018-03-01 2022-03-29 Novan, Inc. Nitric oxide releasing suppositories and methods of use thereof
US10716805B2 (en) 2018-03-19 2020-07-21 Glanotech Limited Formulation for release of nitric oxide
WO2020245574A1 (en) 2019-06-04 2020-12-10 Thirty Respiratory Limited Methods and compositions for generating nitric oxide and uses thereof to deliver nitric oxide via the respiratory tract
WO2020245573A1 (en) 2019-06-04 2020-12-10 Thirty Holdings Limited Methods and compositions for generating nitric oxide and uses thereof
WO2021214439A1 (en) 2020-04-23 2021-10-28 Thirty Respiratory Limited Methods and compositions for treating and combatting tuberculosis
WO2021214440A1 (en) 2020-04-23 2021-10-28 Thirty Respiratory Limited Nitric oxide or nitric oxide releasing compositions for use in treating sars-cov and sars-cov-2

Also Published As

Publication number Publication date
CA2322199A1 (en) 1999-09-10
HUP0101374A3 (en) 2003-07-28
KR20010041527A (ko) 2001-05-25
JP2002505295A (ja) 2002-02-19
NZ506678A (en) 2003-04-29
NO20004302L (no) 2000-10-30
MXPA00008583A (es) 2003-07-14
PL342755A1 (en) 2001-07-02
GB9804469D0 (en) 1998-04-29
CN1291897A (zh) 2001-04-18
AU3261799A (en) 1999-09-20
BR9908617A (pt) 2000-12-05
HUP0101374A2 (hu) 2001-08-28
AU758264B2 (en) 2003-03-20
CN1270725C (zh) 2006-08-23
EP1059928A1 (en) 2000-12-20
NO20004302D0 (no) 2000-08-29

Similar Documents

Publication Publication Date Title
AU758264B2 (en) Inorganic nitrite and organic acid in combination as topical antiviral composition
US6709681B2 (en) Acidified nitrite as an antimicrobial agent
EP1064946B1 (en) Topical zinc compositions
Ågren Studies on zinc in wound healing
US4503037A (en) Composition for the treatment of epithelial injuries and process for the preparation thereof
US7198806B2 (en) Composition and method for treatment and prevention of pruritis
US20030147970A1 (en) Ionic silver complex
JP4700808B2 (ja) フルボ酸、および種々の状態の処置におけるその使用
JP4987209B2 (ja) 瘢痕形成作用を有する医薬品を製造するためのビグアニド誘導体の使用
KR20070092095A (ko) 소독용 조성물 및 이의 제조 및 이용 방법
AU645359B2 (en) Lithium treatment
RU2636530C2 (ru) Фармацевтическая композиция для лечения ран и ожогов
JP2005501068A (ja) 特に眼科分野における適用のための外傷および損傷の治癒および／または修復のための治療に適したアミノ酸組成物
RU2481834C2 (ru) Антимикробная композиция для лечения ран и ожогов
JP2024509309A (ja) 三環式ヘテロアリール基を有する化合物の用途
JPS6054932B2 (ja) 治療組成物
CZ289788B6 (cs) Topický přípravek pro zavádění peptidických farmak do ľivých organismů
JP3827259B2 (ja) 表皮角質化促進剤
RU2717674C1 (ru) Лекарственное средство, усиливающее оксигенацию тканей при диабетической стопе, и способ его применения
CZ20003204A3 (cs) Farmaceutický prostředek
MXPA00005595A (en) Topical zinc compositions and methods of use

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 99803586.6

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2322199

Country of ref document: CA

Ref document number: 2322199

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 506678

Country of ref document: NZ

Ref document number: 32617/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: PA/a/2000/008583

Country of ref document: MX

Ref document number: 1020007009698

Country of ref document: KR

Ref document number: PV2000-3204

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 1999937878

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999937878

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV2000-3204

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 1020007009698

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 32617/99

Country of ref document: AU

WWR Wipo information: refused in national office

Ref document number: 1020007009698

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: PV2000-3204

Country of ref document: CZ

WWR Wipo information: refused in national office

Ref document number: 1999937878

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1999937878

Country of ref document: EP